Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Queensland Health
US Department of Justice
Cerilliant
Cantor Fitzgerald
Chubb
Baxter
Federal Trade Commission
Johnson and Johnson

Generated: November 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020929

« Back to Dashboard

NDA 020929 describes PULMICORT RESPULES, which is a drug marketed by Astrazeneca Pharms and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and two Paragraph IV challenges. Additional details are available on the PULMICORT RESPULES profile page.

The generic ingredient in PULMICORT RESPULES is budesonide. There are twenty-one drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the budesonide profile page.
Summary for 020929
Tradename:PULMICORT RESPULES
Applicant:Astrazeneca Pharms
Ingredient:budesonide
Patents:3
Formulation / Manufacturing:see details
Pharmacology for NDA: 020929
Medical Subject Heading (MeSH) Categories for 020929
Suppliers and Packaging for NDA: 020929
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PULMICORT RESPULES budesonide SUSPENSION;INHALATION 020929 NDA AstraZeneca Pharmaceuticals LP 0186-1988 0186-1988-04 6 POUCH in 1 CARTON (0186-1988-04) > 5 AMPULE in 1 POUCH > 2 mL in 1 AMPULE
PULMICORT RESPULES budesonide SUSPENSION;INHALATION 020929 NDA AstraZeneca Pharmaceuticals LP 0186-1989 0186-1989-04 6 POUCH in 1 CARTON (0186-1989-04) > 5 AMPULE in 1 POUCH > 2 mL in 1 AMPULE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION;INHALATIONStrength0.25MG/2ML
Approval Date:Aug 8, 2000TE:ANRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jun 23, 2019Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Try a Free TrialPatent Expiration:Jun 23, 2019Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Try a Free TrialPatent Expiration:May 11, 2019Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 020929

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca Pharms PULMICORT RESPULES budesonide SUSPENSION;INHALATION 020929-003 Aug 8, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms PULMICORT RESPULES budesonide SUSPENSION;INHALATION 020929-001 Aug 8, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms PULMICORT RESPULES budesonide SUSPENSION;INHALATION 020929-002 Aug 8, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Harvard Business School
Moodys
Daiichi Sankyo
US Army
Express Scripts
Chinese Patent Office
Boehringer Ingelheim
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.